Medicare Will Cover GLP-1 Weight Loss Drugs Starting July 2026: What You Need to Know
Author
glp winnerDate Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
Starting July 1, 2026, Medicare will cover Wegovy and Zepbound for weight loss at a flat $50 per month copay through a new temporary program called the Medicare GLP-1 Bridge (CMS). This is the first time Medicare has ever covered prescription medications specifically for obesity, after a federal ban on that coverage that lasted more than 20 years.
Who This Helps
This guide is for anyone on Medicare who has wondered whether they could get help paying for a GLP-1 weight loss medication. It is especially useful if you are 65 or older, on disability, have been told these drugs are too expensive, or have been confused by the back-and-forth news about whether Medicare would ever cover them. If you are newer to GLP-1 medications in general, our GLP-1 basics guide is a good place to start.
Why This Is a Big Deal
Until now, Medicare was not allowed to pay for weight loss drugs. Period. Congress banned it in 2003 when it created Medicare Part D (ASPE). At the time, the weight loss medications available were not very effective and had serious safety problems, so lawmakers decided they were cosmetic and excluded them from coverage.
That exclusion stayed in place even after GLP-1 medications changed the picture completely. More than one-third of Medicare beneficiaries are obese, and another 35% are overweight (KFF). But if you were on Medicare and wanted Wegovy or Zepbound for weight loss, you had to pay full price out of pocket. That could mean $1,000 or more per month.
The Medicare GLP-1 Bridge changes that, at least temporarily. It runs from July 1 through December 31, 2026. After that, a longer program called the BALANCE Model is expected to take over starting January 2027 (CMS).
Which Drugs Are Covered
The Medicare GLP-1 Bridge covers two FDA-approved weight loss medications:
- Wegovy (semaglutide), including the new oral tablet and the injection
- Zepbound (tirzepatide) injection
These are the only GLP-1 drugs covered specifically for weight loss under this program. If you are comparing the two, our article on tirzepatide vs. semaglutide breaks down how they differ.
What about Ozempic and Mounjaro?
Ozempic (semaglutide) and Mounjaro (tirzepatide) are the same ingredients as Wegovy and Zepbound, but they are FDA-approved for type 2 diabetes, not weight loss. Medicare Part D already covers Ozempic and Mounjaro for diabetes. The GLP-1 Bridge does not change that. This program only adds coverage for the weight loss versions: Wegovy and Zepbound.
If you are confused about the difference between these drug names, our guide on why GLP-1 medication names change explains how the same ingredient can have different brand names for different uses.
What About the Wegovy Pill?
Yes, the Wegovy pill (oral semaglutide for weight loss) is covered under the Medicare GLP-1 Bridge (CMS). The FDA approved the once-daily oral Wegovy tablet in December 2025, and it is already available in more than 70,000 pharmacies. This is a big deal for anyone who does not want to use an injection. If you are deciding between the shot and the pill, keep in mind that both are covered at the same $50 per month copay.
Who Qualifies for Medicare GLP-1 Coverage
To use the Medicare GLP-1 Bridge, you need to meet all of the following (CMS):
- You are at least 18 years old
- You are enrolled in a Medicare Part D plan (either a standalone Part D plan or a Medicare Advantage plan with drug coverage)
- Your doctor submits a prior authorization confirming that you meet the clinical requirements
The clinical requirements are:
- BMI of 35 or higher, with no other conditions required, OR
- BMI of 27 or higher with at least one of these conditions:
- Prediabetes
- Cardiovascular disease (heart disease)
- Uncontrolled high blood pressure
- Chronic kidney disease
- Heart failure
Your doctor will also need to confirm that the medication is being prescribed along with lifestyle changes, meaning structured nutrition and physical activity. This does not mean you need to be in a formal program. But it does mean your provider needs to be working with you on diet and exercise alongside the medication.
If you are not sure whether your BMI qualifies, your doctor can measure it at a regular visit. A BMI of 27 is roughly 160 pounds at 5'4" or 180 pounds at 5'8". A BMI of 35 is roughly 205 pounds at 5'4" or 230 pounds at 5'8".
How Much Will It Cost
Under the Medicare GLP-1 Bridge, the cost is simple: $50 per month flat copay (CMS). That is the same whether you take Wegovy (injection or pill) or Zepbound.
For context, without insurance:
- Wegovy injection costs roughly $1,300 per month
- Zepbound injection costs roughly $1,000 per month
- The Wegovy pill starts at about $149 per month through Novo Nordisk's direct pricing, but the Medicare copay is even lower
One important detail: The $50 copay you pay under the GLP-1 Bridge does not count toward your Medicare Part D annual out-of-pocket cap (which is $2,100 in 2026). The Bridge program runs alongside your normal Part D coverage, not through it. That means your GLP-1 costs will not help you reach the cap faster, but they also will not eat into your cap for other medications.
If you are already looking at ways to lower your GLP-1 costs, our article on how insurance coverage for GLP-1s really works covers the broader picture beyond Medicare.
What Is Prior Authorization and How Does It Work
Prior authorization means your doctor needs to get approval before you can fill the prescription. Under the Medicare GLP-1 Bridge, here is how it works (CMS):
- Your doctor submits a request to a central processor run by CMS (not your individual Part D plan)
- The request confirms your BMI, qualifying conditions, and that the drug is being prescribed with lifestyle changes
- Once approved, you can fill the prescription at any pharmacy. Pharmacies do not need to opt in to the program separately.
CMS will release more details on the approval timeline and the appeals process in Spring 2026. If you are planning to start in July, it is a good idea to talk to your doctor now so you are ready to submit the authorization as soon as the program opens.
Our guide on how to ask your doctor for a GLP-1 prescription has tips on starting that conversation.
The Timeline: What Happens When
Here is the full timeline for Medicare GLP-1 coverage:
- Now through June 2026: No Medicare coverage for weight loss GLP-1 drugs. You pay out of pocket or use other savings programs. CMS will release more program details in Spring 2026.
- July 1, 2026: The Medicare GLP-1 Bridge launches. Wegovy and Zepbound are covered at $50 per month for qualifying beneficiaries.
- December 31, 2026: The Bridge program ends.
- January 1, 2027: The BALANCE Model is expected to begin for Medicare Part D plans that choose to participate. This is a five-year program running through December 2031.
- Fall 2026 (Open Enrollment): If your current Part D plan does not participate in BALANCE, you may need to switch to a plan that does during Medicare open enrollment (October 15 through December 7, 2026).
What this means for you: The Bridge gives you six months of $50/month access. But to keep coverage in 2027 and beyond, you will need to be in a Part D plan that joins the BALANCE Model. Not all plans are required to participate, so check during open enrollment.
What You Should Do Right Now to Prepare
If you are on Medicare and interested in GLP-1 coverage, here are the steps to take before July:
- Talk to your doctor. Get your BMI measured. Ask whether you meet the clinical criteria (BMI of 35 or higher, or BMI of 27 or higher with prediabetes, heart disease, high blood pressure, kidney disease, or heart failure). If you qualify, ask your provider to be ready to submit the prior authorization when the program opens.
- Confirm your Part D enrollment. You need active Medicare Part D coverage to use the Bridge. If you are in Original Medicare without Part D, or if your plan does not include drug coverage, you may need to enroll or switch plans before you can use this plan.
- Start lifestyle changes now. The program requires that the medication be used alongside structured nutrition and physical activity. Starting those habits now means you are ready on day one. Our article on meal planning when you are not hungry on GLP-1s and our bodyweight exercise guide for GLP-1 users can help.
- Watch for updates from CMS. More details on the program design, the approval process, and the appeals process are coming in Spring 2026. You can check the CMS Medicare GLP-1 Bridge page for updates.
- Plan ahead for 2027. During Medicare open enrollment this fall, check whether your Part D plan will participate in the BALANCE Model for 2027. If it will not, consider switching to one that does so you can keep your GLP-1 coverage without a gap.
What the Bridge Does Not Cover
There are a few things this program does not include:
- Compounded GLP-1 medications are not covered. The Bridge only covers FDA-approved brand-name Wegovy and Zepbound. If you are currently using a compounded medication, our article on how to evaluate telehealth and compounded GLP-1 providers can help you understand your options.
- Ozempic and Mounjaro for weight loss are not covered through this program. Those drugs are covered by Medicare Part D only when prescribed for type 2 diabetes.
- Rybelsus (oral semaglutide for diabetes) may be included in the broader BALANCE Model starting in 2027, but CMS has not confirmed whether it is part of the Bridge.
- Coverage beyond six months is not guaranteed. The Bridge ends December 31, 2026. Continued coverage depends on your Part D plan joining the BALANCE Model.
Will Coverage Continue After the Bridge Ends?
That depends on the BALANCE Model. BALANCE is a five-year demonstration program that CMS plans to launch for Medicare in January 2027 (CMS). Under BALANCE, Part D plans can voluntarily participate and offer GLP-1 weight loss drugs to their members at negotiated prices.
The key word is "voluntarily." Not every Part D plan is required to join. CMS has said that if fewer than 80% of Part D plan sponsors participate, it may not launch the Medicare portion of BALANCE in 2027 at all (KFF).
This means there is a real possibility that some people could have coverage for six months under the Bridge and then lose access in January 2027. That is why it is important to pay attention during open enrollment in Fall 2026 and choose a plan that has committed to BALANCE if you want to stay on your medication.
If you are worried about what happens when you stop a GLP-1, our articles on what happens when you stop taking a GLP-1 and new trial data on GLP-1 discontinuation cover what the research shows.
How This Affects People on Medicare Advantage
If you have a Medicare Advantage plan with prescription drug coverage (MA-PD), you are eligible for the GLP-1 Bridge just like anyone on a standalone Part D plan (CMS). The Bridge runs through a central CMS processor, not through your individual plan, so it works the same regardless of which Part D plan you are in.
For 2027 and beyond, your Medicare Advantage plan would need to participate in the BALANCE Model to continue covering GLP-1s for weight loss. If your current MA plan does not join, you would need to switch plans during open enrollment.
What Does This Cost Medicare?
The Congressional Budget Office estimated that covering anti-obesity medications for Medicare beneficiaries would cost roughly $35 billion over 10 years, with about $3 billion in health care savings from fewer hospitalizations and complications (CBO). The administration's approach uses negotiated pricing with manufacturers to keep costs lower. Under the Bridge, Medicare pays a net price of $245 per month per patient, with the patient paying $50 of that.
About 6 million to 14 million Medicare beneficiaries have a diagnosis of obesity. CMS projects about 300,000 people will use the Bridge in its first year (KFF).
Side Effects and What to Expect When Starting
If this is your first time considering a GLP-1 medication, it helps to know what the common side effects are before you start. Most people experience some nausea, especially during the first few weeks as your dose increases. Other common side effects include stomach discomfort, constipation, and reduced appetite.
Our detailed guides on the most common GLP-1 side effects, long-term side effects, and foods that can ease or worsen side effects can help you prepare. If you want to separate fact from rumor, our side effect myth busters article is a good read.
Final Takeaway
For the first time in over 20 years, Medicare will help pay for GLP-1 weight loss medications. The program is temporary, it comes with conditions, and the long-term picture depends on what happens with the BALANCE Model in 2027. But for millions of people on Medicare who could not afford these drugs before, July 2026 is a real turning point. If you think you might qualify, the smartest thing you can do right now is talk to your doctor, confirm your Part D enrollment, and start building the lifestyle habits that will make the medication work best.
If you are not on Medicare and want to explore your options, GLP Winner's provider comparison tool can help you find a GLP-1 provider that fits your budget and needs.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Sources
Keep Reading
Eli Lilly claims B12 in compounded GLP-1s creates an impurity. We break down what the data shows, what's missing, and whether you should worry.
Novo Nordisk and Hims struck a deal on Ozempic and Wegovy pricing. See what it means for GLP-1 costs, compounded access, and your options.
Learn how TrumpRx coupons work, who qualifies, where they’re accepted, and what to watch for before starting GLP-1 meds long term.
Categories
Curated by
